The combination of PD-1/PD-L1 blockade with other immune checkpoint inhibitors, like anti-CTLA-4 or anti-angiogenic agents such as anti-VEGFR inhibitors, represents an enhanced therapeutic strategies for NPC. The gene discussed is CTLA4; the disease is nasopharyngeal carcinoma.